查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1842169

全球乳癌診斷市場：市場規模、佔有率、趨勢分析（按產品、類型、應用、最終用途和地區分類）、細分市場預測（2025-2033 年）

Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

乳癌診斷市場摘要

全球乳癌診斷市場預計在 2024 年達到 54.8 億美元，預計到 2033 年將達到 113.6 億美元，2025 年至 2033 年的複合年成長率為 8.6%。

這一成長歸因於癌症發病率的上升以及政府為提高篩檢和診斷率而採取的措施不斷增加。

乳癌發生率的上升預計將推動乳癌診斷市場的發展。根據美國癌症協會發布的《2024年乳癌事實與數據》，乳癌仍是美國女性最常見的癌症。預計2024年將新增310,720例侵襲性乳癌病例，以及55,720例乳管原位癌（DCIS）病例。

多種因素導致乳癌發生率上升，包括人口老化、生活方式改變、遺傳易感性和環境影響。隨著預期壽命的延長，越來越多的女性步入乳癌高發生率。此外，肥胖、久坐不動的生活方式、荷爾蒙療法和延遲生育等風險因素也與更高的乳癌發生率有關。公眾意識的提高和篩檢計畫的改進使得更多癌症得以早期發現，從而增加了報告病例數。乳癌病例的增加凸顯了對高效能精準診斷技術的需求。雖然乳房X光攝影仍然是乳癌篩檢的黃金標準，但數位乳房斷層合成（DBT）、造影乳房X光乳房X光攝影、超音波、磁振造影（MRI）和分子診斷檢測等技術的進步推動了市場成長。人工智慧在影像解讀的應用進一步提高了早期檢測能力，提高了準確性，同時減少了假陽性和假陰性。此外，液態切片和基於生物標記的診斷方法已成為檢測乳癌和監測治療效果的非侵入性工具。

為了應對日益嚴重的乳癌負擔，全球醫療衛生系統加大了對乳癌篩檢計畫的投入。各國政府和私人醫療機構擴大了診斷服務的覆蓋範圍，尤其是在篩檢率歷來較低的發展中地區。對早期檢測和個人化醫療的重視加速了次世代定序儀（NGS）、基因檢測和伴隨診斷技術的應用。隨著乳癌發病率的持續上升，乳癌診斷市場也經歷了持續成長。技術的不斷進步，以及篩檢意識的提高和可及性的增強，推動了對能夠實現更早期、更精準癌症檢測的創新診斷解決方案的需求。

乳癌篩檢報銷和保險覆蓋範圍的擴大預計將推動市場成長。包括德國聯邦聯合委員會在內的多個國家政府機構已核准此項檢測納入全國報銷範圍。在美國，醫療補助計劃（Medicaid）、醫療保險計劃（Medicare）和第三方支付機構均涵蓋乳癌基因檢測（包括BRCA1和BRCA2基因檢測）的費用，且全球範圍內的檢測數量正在增加。此外，醫療保險B部分（Medicare Part B）為40歲及以上女性每年一次的乳房X光攝影和數位乳房X光攝影檢查提供80%的費用報銷。

2025年2月，Agendia宣布，布魯塞爾國家疾病與意外保險研究所（INAMI-RIZIV）已擴大MammaPrint的報銷範圍，將其用於新輔助治療。自2025年1月1日起，該決定將使HR+/HER2陰性早期乳癌患者獲得全額報銷，從而使粗針穿刺切片的基因組檢測能夠指南新輔助治療方案的製定。此次報銷範圍的擴大標誌著在為患者提供更個人化的醫療服務方面邁出了重要一步。布魯塞爾自由大學腫瘤學榮譽教授馬丁·皮卡特教授強調了這項進展的影響，她表示：“在比利時，MammaPrint技術應用於粗針穿刺切片檢體是乳癌個性化治療領域的一個重要里程碑。它在新輔助治療方面具有顯著優勢，使醫生能夠更精準地制定治療方案，尤其是在MammaPrint指導下。如果選擇合適的治療次數，這將有可能減少手術次數。

MammaPrint 在新輔助治療中展現出卓越的性能，尤其是在 FLEX (NCT03053193) 等研究中。 FLEX 是一項前瞻性、真實世界觀察性研究，以全轉錄組分析法研究乳癌。此檢測方法在匹配的手術切除標本和穿刺活體組織切片標本之間顯示出高度一致性，進一步增強了其臨床效用。此適應症的擴大凸顯了基因組檢測在乳癌管理中的重要作用，有助於制定更精準的治療策略。 Agendia執行長強調了此次醫保覆蓋範圍擴大的重要意義，他表示：「MammaPrint 醫保覆蓋範圍的擴大是抗擊乳癌的重要一步。這一決定將使更多比利時女性能夠獲得 Agendia 的先進診斷解決方案，這些方案是製定個性化治療方案的基礎。我們感謝 INAMI-RIZIV 認可精準醫療效果的重要性，並期待繼續致力於改善比利時乳癌的患者的效果。」

總體而言，技術的進步以及報銷和保險覆蓋範圍的擴大，顯著提高了乳癌的診斷水平，從而實現了早期發現、標靶治療和患者預後改善。隨著技術的不斷發展，持續的研究和開發對於進一步提高乳癌的診斷水平至關重要。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章 市場因素、趨勢與範圍

  • 市場關聯性展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場趨勢與展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • PESTEL 分析
    • 波特五力分析
  • 新冠疫情影響分析

第4章 按類型進行業務分析

  • 乳癌診斷市場：類型差異分析，2024 年和 2033 年
  • 影像診斷
    • 診斷影像市場（2021-2033）
  • 切片檢查
    • 切片檢查市場（2021-2033）
  • 基因組檢測
    • 基因組檢測市場（2021-2033）
  • 血液檢查
    • 血液檢測市場（2021-2033）
  • 其他
    • 其他市場（2021-2033 年）

第5章：依產品進行業務分析

  • 乳癌診斷市場：按產品分類的趨勢分析（2024 年和 2033 年）
  • 基於平台的產品
    • 平台型產品市場（2021-2033）
    • 次世代定序
    • 微陣列
    • PCR
    • 其他
  • 設備類產品
    • 設備型產品市場（2021-2033）
    • 影像診斷
    • 切片檢查

第6章：按應用程式進行業務分析

  • 乳癌診斷市場：按應用領域分類的趨勢分析（2024 年和 2033 年）
  • 篩檢
    • 篩檢市場（2021-2033）
  • 診斷與預測
    • 診斷與預測市場（2021-2033）
  • 預後
    • 預測市場（2021-2033）
  • 研究
    • 研究市場（2021-2033）

第7章 依最終用途進行業務分析

  • 乳癌診斷市場：按最終用途分類的趨勢分析（2024 年和 2033 年）
  • 醫院和診所
    • 醫院和診所市場（2021-2033 年）
  • 醫學實驗室/診斷中心
    • 醫療實驗室和診斷中心市場（2021-2033）
  • 其他
    • 其他市場（2021-2033 年）

第8章：區域商業分析

  • 市場概述：按地區分類
  • 北美洲
    • 北美乳癌診斷市場（2021-2033）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲乳癌診斷市場（2021-2033）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區乳癌診斷市場（2021-2033）
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 拉丁美洲乳癌診斷市場（2021-2033）
    • 主要國家的趨勢
    • 法律規範
    • 競爭場景
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲乳癌診斷市場（2021-2033）
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 公司分類
  • 策略規劃
    • 企業收購
    • 商業合作
    • 新平台推出
    • 其他
  • 公司簡介/上市公司
    • Hologic Inc.
    • Genomic Health（Exact Sciences Corporation）
    • BD
    • Danaher
    • Koninklijke Philips NV
    • QIAGEN
    • Thermo Fisher Scientific Inc
    • Myriad Genetics
    • Argon Medical Devices, Inc.
    • F. Hoffmann-La Roche Ltd.
Product Code: GVR-3-68038-694-3

Breast Cancer Diagnostics Market Summary

The global breast cancer diagnostics market size was estimated at USD 5.48 billion in 2024 and is projected to reach USD 11.36 billion by 2033, growing at a CAGR of 8.6% from 2025 to 2033. The growth can be attributed to the increasing prevalence of cancer and rising government initiatives to increase the screening and diagnostic rate.

The increasing incidence of breast cancer is expected to drive the breast cancer diagnostics market. According to the American Cancer Society's Breast Cancer Facts & Figures 2024, breast cancer remained the most commonly diagnosed cancer among women in the United States. In 2024, an estimated 310,720 new cases of invasive breast cancer were expected to be diagnosed, along with 55,720 cases of ductal carcinoma in situ (DCIS).

Several factors contributed to the increasing incidence of breast cancer, including aging populations, lifestyle changes, genetic predisposition, and environmental influences. As life expectancy increased, more women reached ages where breast cancer risk was higher. Moreover, risk factors such as obesity, sedentary lifestyles, hormonal therapies, and delayed childbearing were linked to a greater likelihood of developing breast cancer. Increased awareness and improved screening programs also led to a rise in reported cases, as more cancers were detected at earlier stages. With the growing number of breast cancer cases, the need for effective and accurate diagnostic technologies expanded. Mammography remained the gold standard for breast cancer screening, but advancements in digital breast tomosynthesis (DBT), contrast-enhanced mammography, ultrasound, MRI, and molecular diagnostic tests drove market growth. The integration of AI in imaging interpretation further improved early detection capabilities, enhancing accuracy while reducing false positives and negatives. In addition, liquid biopsy and biomarker-based diagnostics emerged as non-invasive tools for detecting breast cancer and monitoring treatment response.

Healthcare systems worldwide increased investments in breast cancer screening programs to address the rising burden. Governments and private healthcare providers expanded access to diagnostic services, particularly in developing regions where screening rates had historically been lower. The focus on early detection and personalized medicine accelerated the adoption of next-generation sequencing (NGS), genetic testing, and companion diagnostics. As breast cancer incidence continued to rise, the breast cancer diagnostics market experienced sustained growth. Ongoing technological advancements, combined with greater awareness and improved accessibility to screening, drove demand for innovative diagnostic solutions that enabled earlier and more accurate cancer detection.

The increasing reimbursement and insurance coverage for breast cancer testing is anticipated to drive market growth. Government agencies in various countries, such as the German Federal Joint Committee, have approved tests for nationwide reimbursement. In the U.S., Medicaid, Medicare, and third-party payer benefit plans cover the cost of breast cancer genetic testing, including BRCA1 and BRCA2 tests, increasing the number of procedures conducted globally. Furthermore, Medicare Part B covers 80% of the cost of one mammogram and digital mammogram screening per year for women aged 40 and older.

In February 2025, Agendia, Inc. announced that the National Institute for Sickness and Invalidity Insurance (INAMI-RIZIV) in Brussels expanded the reimbursement criteria for MammaPrint, now covering its use in the neoadjuvant setting. Effective January 1, 2025, this decision allows full reimbursement for patients with HR+/HER2-negative early-stage breast cancer, enabling genomic testing on core needle biopsies to guide neoadjuvant treatment decisions. This expansion marks a significant step forward in providing patients with more personalized care. Professor Martine Piccart, Honorary Professor of Oncology at the Universite Libre de Bruxelles, highlighted the impact of this advancement, stating, "The ability to use MammaPrint on core needle biopsy specimens in Belgium represents a major milestone for personalized breast cancer treatment. The benefits of neoadjuvant therapy are substantial, especially when guided by MammaPrint, as it enables physicians to tailor treatment plans more precisely. This can lead to less extensive surgical procedures when the appropriate treatment is selected."

MammaPrint has demonstrated strong performance in the neoadjuvant setting, particularly through studies like FLEX (NCT03053193), a prospective, real-world observational breast cancer study utilizing whole transcriptome analysis. The assay has shown high concordance between matched surgical resection samples and core needle biopsy specimens, reinforcing its clinical utility. This expanded indication underscores the critical role of genomic testing in breast cancer management, supporting more precise treatment strategies. Chief Executive Officer at Agendia, emphasized the significance of this reimbursement expansion, stating, "The broader reimbursement of MammaPrint represents a major step forward in the fight against breast cancer. This decision ensures that more women in Belgium likely to access to Agendia's advanced diagnostic solutions, which serve as the foundation for personalized treatment decisions. We are grateful for INAMI-RIZIV's recognition of the importance of precision medicine and look forward to continuing our commitment to improving outcomes for breast cancer patients in Belgium.

Overall technological advancements, along with increasing reimbursement and insurance coverage, have significantly improved breast cancer diagnostics, leading to earlier detection, targeted treatments, and improved patient outcomes. Ongoing research and development efforts are essential to enhance breast cancer diagnostics further as technology continues to evolve.

Global Breast Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global breast cancer diagnostics market report based on type, product, application, end use, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Imaging
  • Biopsy
  • Genomic Tests
  • Blood Tests
  • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Platform-based products
    • Next Generation Sequencing
    • Microarrays
    • PCR
    • Others
  • Instrument-based products
    • Imaging
    • Biopsy
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Screening
  • Diagnostic & Predictive
  • Prognostic
  • Research
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Medical labs & Diagnostics Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Market Definitions
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Product Snapshot
  • 2.3. Application and End-use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Business Environment Analysis
    • 3.4.1. PESTLE Analysis
    • 3.4.2. Porter's Five Forces Analysis
  • 3.5. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Breast Cancer Diagnostics Market: Type Movement Analysis, 2024 & 2033
  • 4.2. Imaging
    • 4.2.1. Imaging Market, 2021 - 2033 (USD Million)
  • 4.3. Biopsy
    • 4.3.1. Biopsy Market, 2021 - 2033 (USD Million)
  • 4.4. Genomic Tests
    • 4.4.1. Genomic Tests Market, 2021 - 2033 (USD Million)
  • 4.5. Blood Tests
    • 4.5.1. Blood Tests Market, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Product Business Analysis

  • 5.1. Breast Cancer Diagnostics Market: Product Movement Analysis, 2024 & 2033
  • 5.2. Platform-based products
    • 5.2.1. Platform-based Products Market, 2021 - 2033 (USD Million)
    • 5.2.2. Next Generation Sequencing
      • 5.2.2.1. Next Generation Sequencing market, 2021 - 2033 (USD Million)
    • 5.2.3. Microarrays
      • 5.2.3.1. Microarrays market, 2021 - 2033 (USD Million)
    • 5.2.4. PCR
      • 5.2.4.1. PCR market, 2021 - 2033 (USD Million)
    • 5.2.5. Others
      • 5.2.5.1. Others market, 2021 - 2033 (USD Million)
  • 5.3. Instrument-based products
    • 5.3.1. Instrument-based Products Market, 2021 - 2033 (USD Million)
    • 5.3.2. Imaging
      • 5.3.2.1. Imaging market, 2021 - 2033 (USD Million)
    • 5.3.3. Biopsy
      • 5.3.3.1. Biopsy market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

  • 6.1. Breast Cancer Diagnostics Market: Application Movement Analysis, 2024 & 2033
  • 6.2. Screening
    • 6.2.1. Screening Market, 2021 - 2033 (USD Million)
  • 6.3. Diagnostic & Predictive
    • 6.3.1. Diagnostic & Predictive Market, 2021 - 2033 (USD Million)
  • 6.4. Prognostic
    • 6.4.1. Prognostic Market, 2021 - 2033 (USD Million)
  • 6.5. Research
    • 6.5.1. Research Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Breast Cancer Diagnostics Market: End-use Movement Analysis, 2024 & 2033
  • 7.2. Hospitals & Clinics
    • 7.2.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
  • 7.3. Medical labs & Diagnostics Centers
    • 7.3.1. Medical labs & Diagnostics Centers Market, 2021 - 2033 (USD Million)
  • 7.4. Others
    • 7.4.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Regional Market Snapshot
  • 8.2. North America
    • 8.2.1. North America Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.2.2. Key Country Dynamics
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Competitive Scenario
    • 8.2.3. Canada
      • 8.2.3.1. Canada Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.3.2. Key Country Dynamics
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Competitive Scenario
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.4.2. Key Country Dynamics
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Competitive Scenario
  • 8.3. Europe
    • 8.3.1. Europe Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Germany Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.2.2. Key Country Dynamics
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Competitive Scenario
    • 8.3.3. UK
      • 8.3.3.1. UK Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.3.2. Key Country Dynamics
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Competitive Scenario
    • 8.3.4. France
      • 8.3.4.1. France Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.4.2. Key Country Dynamics
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Competitive Scenario
    • 8.3.5. Italy
      • 8.3.5.1. Italy Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.5.2. Key Country Dynamics
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Competitive Scenario
    • 8.3.6. Spain
      • 8.3.6.1. Spain Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.6.2. Key Country Dynamics
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Competitive Scenario
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.7.2. Key Country Dynamics
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Competitive Scenario
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.8.2. Key Country Dynamics
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Competitive Scenario
    • 8.3.9. Norway
      • 8.3.9.1. Norway Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.9.2. Key Country Dynamics
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Competitive Scenario
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.2.2. Key Country Dynamics
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Competitive Scenario
    • 8.4.3. China
      • 8.4.3.1. China Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.3.2. Key Country Dynamics
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Competitive Scenario
    • 8.4.4. India
      • 8.4.4.1. India Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.4.2. Key Country Dynamics
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Competitive Scenario
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.5.2. Key Country Dynamics
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Competitive Scenario
    • 8.4.6. Australia
      • 8.4.6.1. Australia Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.6.2. Key Country Dynamics
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Competitive Scenario
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.7.2. Key Country Dynamics
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Competitive Scenario
  • 8.5. Latin America
    • 8.5.1. Latin America Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.2. Key Country Dynamics
    • 8.5.3. Regulatory Framework
    • 8.5.4. Competitive Scenario
    • 8.5.5. Brazil
      • 8.5.5.1. Brazil Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.5.2. Key Country Dynamics
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Competitive Scenario
    • 8.5.6. Argentina
      • 8.5.6.1. Argentina Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.6.2. Key Country Dynamics
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Competitive Scenario
  • 8.6. MEA
    • 8.6.1. MEA Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.2.2. Key Country Dynamics
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Competitive Scenario
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.3.2. Key Country Dynamics
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Competitive Scenario
    • 8.6.4. UAE
      • 8.6.4.1. UAE Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.4.2. Key Country Dynamics
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Competitive Scenario
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.5.2. Key Country Dynamics
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Competitive Scenario

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. Acquisition
    • 9.2.2. Collaborations
    • 9.2.3. New Platform Launches
    • 9.2.4. Others
  • 9.3. Company Profiles/Listing
    • 9.3.1. Hologic Inc.
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Platform Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Genomic Health (Exact Sciences Corporation)
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Platform Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. BD
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Platform Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Danaher
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Platform Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Koninklijke Philips N.V
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Platform Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. QIAGEN
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Platform Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Thermo Fisher Scientific Inc
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Platform Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Myriad Genetics
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Platform Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Argon Medical Devices, Inc.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Platform Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. F. Hoffmann-La Roche Ltd.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Platform Benchmarking
      • 9.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 4 Global Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 5 Global Breast Cancer Diagnostics Market, by Application, 2021 - 2033 (USD Million)
  • Table 6 Global Breast Cancer Diagnostics Market, by End-use, 2021 - 2033 (USD Million)
  • Table 7 Global Breast Cancer Diagnostics Market, by Region, 2021 - 2033 (USD Million)
  • Table 8 North America Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 9 North America Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 10 North America Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 11 North America Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 12 North America OTC US Breast Cancer Diagnostics Market, by End-use, 2021 - 2033 (USD Million)
  • Table 13 U.S. Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 14 U.S. Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 15 U.S. Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 16 U.S. Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 17 Canada Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 18 Canada Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 19 Canada Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 20 Canada Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 21 Mexico Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 22 Mexico Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 23 Mexico Breast Cancer Diagnostics Market, by Application, 2021 - 2033 (USD Million)
  • Table 24 Mexico Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 25 Europe Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 26 Europe Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 27 Europe Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 28 Europe Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 29 Europe Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 30 UK Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 31 UK Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 32 UK Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 33 UK Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 34 Germany Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 35 Germany Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 36 Germany Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 37 Germany Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 38 France Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 39 France Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 40 France Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 41 France Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 42 Italy Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 43 Italy Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 44 Italy Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 45 Italy Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 46 Spain Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 47 Spain Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 48 Spain Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 49 Spain Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 50 Norway Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 51 Norway Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 52 Norway Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 53 Norway Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 54 Sweden Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 55 Sweden Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 56 Sweden Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 57 Sweden Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 58 Denmark Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 59 Denmark Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 60 Denmark Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 61 Denmark Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 67 Japan Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 68 Japan Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 69 Japan Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 70 Japan Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 71 China Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 72 China Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 73 China Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 74 China Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 75 India Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 76 India Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 77 India Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 78 India Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 79 Australia Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 80 Australia Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 81 Australia Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 82 Australia Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 83 South Korea Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 84 South Korea Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 85 South Korea Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 86 South Korea Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 87 Thailand Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 88 Thailand Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 89 Thailand Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 90 Thailand Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 91 Latin America Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 92 Latin America Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 93 Latin America Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 94 Latin America Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 95 Latin America Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 96 Brazil Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 97 Brazil Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 98 Brazil Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 99 Brazil Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 100 Argentina Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 101 Argentina Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 102 Argentina Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 103 Argentina Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 104 Middle East Africa Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 105 Middle East Africa Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 106 Middle East Africa Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 107 Middle East Africa Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 108 Middle East Africa Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 109 South Africa Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 110 South Africa Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 111 South Africa Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 112 South Africa Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 117 UAE Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 118 UAE Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 119 UAE Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 120 UAE Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 123 Kuwait Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 124 Kuwait Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic, And Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration & Growth Prospect Mapping, 2024
  • Fig. 15 Global Breast Cancer Diagnostics Market: Type Movement Analysis
  • Fig. 16 Global Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Global Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Global Genomic Tests Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Global Blood Tests Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 Global Other Tests Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Global Breast Cancer Diagnostics Market: Product Movement Analysis
  • Fig. 22 Global Platform-Based Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Global Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Global Biopsy Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Global Instrument-Based Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Global Microarrays Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Global PCR Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Global Next Generation Sequencing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Global Breast Cancer Diagnostics Market: Application Movement Analysis
  • Fig. 31 Global Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Global Diagnostic & Predictive Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Global Prognostic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Global Research Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Global Breast Cancer Diagnostics Market: End-Use Movement Analysis
  • Fig. 36 Global Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Global Medical Labs & Diagnostics Centres Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Regional Marketplace: Key Takeaways
  • Fig. 40 Regional Outlook, 2024 & 2033
  • Fig. 41 Global Breast Cancer Diagnostics Market: Regional Movement Analysis
  • Fig. 42 North America Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 U.S. Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Canada Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Mexico Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Europe Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Germany Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 UK Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 France Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Italy Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Spain Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Denmark Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Sweden Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Norway Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Asia Pacific Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Japan Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 China Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 India Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Australia Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 South Korea Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Thailand Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Latin America Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Brazil Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Argentina Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Middle East And Africa Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 South Africa Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Saudi Arabia Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 UAE Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Kuwait Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)